

Thalidomide-O-C8-NH2 hydrochloride Biochemical

Thalidomide-O-C8-NH2 hydrochloride

CATALOG #
AAA228546


PRODUCT SYNONYMS

Thalidomide-O-C8-NH2 hydrochloride; Thalidomide-O-C8-NH2 hydrochloride biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2636798-38-2
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
7-Deaza-7-propargylamino-dGTP, CAS 587848-73-5



Structure
7-Deaza-7-propargylamino-dGTP, CAS 587848-73-5

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-O-C8-NH2 hydrochloride biochemical	Thalidomide-O-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
References	1. Peng Peng, et al. A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion. BMC Res Notes. 2020 Sep 18;13(1):445.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.